Actively Recruiting
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Led by Nabiqasim Industries (Pvt) Ltd · Updated on 2026-04-17
800
Participants Needed
2
Research Sites
34 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
CONDITIONS
Official Title
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of any gender
- Patients aged between 18-80 years
- Patients having HbA1c 8 % or above
- Patients diagnosed with type II diabetes for more than at least 6 months
- Patients already on at least 2 or more anti-diabetic agents
- Patients not allergic to empagliflozin, linagliptin, or metformin
You will not qualify if you...
- Patients younger than 18 years
- Patients with Type-I diabetes
- Patients having diabetes for less than 6 months
- Patients currently on GLP-1 and GIP treatments
- Pregnant or lactating females
- Patients with decompensated chronic liver disease
- Patients with eGFR less than 30 ml
- Patients with end-stage heart failure (NYHA Class 4)
- Patients allergic to empagliflozin, linagliptin, or metformin
- Patients unwilling to consent
- Patients unable to provide medical history
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Faisalabad clinics
Faisalabad, Punjab Province, Pakistan
Actively Recruiting
2
Aap ka Clinic
Lahore, Punjab Province, Pakistan
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here